Indigo Diabetes Enterprise Replace
BELGIUM – Ghent, December 21, 2021 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Firm’), a pioneering developer of medical options utilizing nanophotonics, right this moment supplies an replace on current and ongoing enterprise actions.
Medical examine progress
The GLOW examine, which was initiated in March 2021 and is the primary in human scientific examine of its steady multi-metabolite (‘CMM’) sensor, was just lately accomplished. GLOW, listed on www.clinicaltrials.gov below the identifier NCT04782934, was designed to guage the protection of the sensor and the short-term integration into the tissue and was a potential, single-center early feasibility examine performed at Antwerp College Hospital, Belgium. Information was additionally collected from the seven examine members and used to develop the machine to permit real-time, steady measurement of key metabolite ranges in adults with diabetes. The GLOW examine outcomes are at the moment being analysed and as a consequence of be submitted for publication within the New 12 months.
In Might, Indigo appointed Paul Moraviec as Chairman of its Board of Administrators. Paul has amassed over three many years of worldwide expertise within the healthcare sector, having held a number of senior management positions and has introduced extremely related diabetes expertise, having been Vice President of Abbott’s Diabetes Care Worldwide division between 2002 and 2007.
As well as, Indigo appointed seven internationally recognised specialists in endocrinology, diabetes and metabolic illness to kind its newly created Scientific Advisory Board (SAB). The SAB members are all leaders of their area and can function a strategic useful resource to Indigo because it progresses its machine and continues its journey to reworking diabetes administration. The SAB, which held its first assembly in June 2021, contains:
Prof. Dr. Tadej Battelino, Head of Division of Endocrinology, Diabetes & Metabolism, School of Drugs, College of Ljubljana, Slovenia
Prof. Dr. Michael C. Riddell, College of Kinesiology & Well being Science, York College, Canada
Prof. Dr. Eric Renard, Head of Division Endocrinology, Diabetes & Metabolism, Medical College, College of Montpellier, France
Prof. Dr. Christophe De Block, Head of Division of Endocrinology, Diabetology and Metabolic illness, College of Antwerp, Belgium
Prof. Dr. Thomas Danne, Director of Division of Normal Pediatrics Endocrinology/Diabetology & Medical Analysis, Hannover Medical College, Germany
Prof. Dr. Ananda Basu, Division of Endocrinology, College of Virginia, USA
Dr. Anne Peters, Keck College of Drugs, College of Southern California, USA
In December 2021, Indigo appointed Daniel Verstappen as VP High quality Assurance and Regulatory Affairs the place he’ll kind a part of the senior administration group. Daniel has roughly 30 years’ expertise working for medical machine firms, most latterly as International VP, High quality, Regulatory Affairs and Normal Administration at Philip Morris, which is at the moment reworking right into a life science firm.
Daniel’s appointment takes the full variety of staff at Indigo to 40, representing nearly a doubling in headcount during the last yr.
Grant awarded to validate subsequent era system
In September, Indigo obtained a €3 million grant from VLAIO, the Flanders organisation for Innovation & Entrepreneurship, to conduct analysis into excessive quantity manufacturing of its next-generation CMM system. Particularly, Indigo will use the grant to validate its CMM system in a large-scale scientific pivotal examine, ENLIGHT.
Earlier this yr, Indigo efficiently closed the DiaMOND grant, awarded in 2018 below the umbrella of the EU Horizon 2020 SME Instrument framework. The grant was used to speed up the event of Indigo’s CMM system, a next-generation Steady Glucose Monitoring (CGM) machine by acquiring extreme scientific occasion prediction knowledge and creating a superb person expertise through the GLOW examine, a first-in-man trial.
Dr Danaë Delbeke, CEO, Inventor and Co-founder of Indigo Diabetes, commented: “I’m very happy with the vital progress made by our multidisciplinary group at Indigo to develop our CMM sensor in 2021. We are trying ahead to sharing the total GLOW trial knowledge when it’s accessible subsequent yr as we proceed to work in direction of our mission of offering an revolutionary, correct and handy monitoring resolution to mild up the lifetime of tens of millions of individuals dwelling with diabetes.”
– Ends –
About Indigo Diabetes N.V.
Indigo Diabetes N.V. (Indigo) is a pioneering developer of medical options using nanophotonics. Indigo was based by Danaë Delbeke and her group in 2016. Right this moment Indigo is creating the world’s first invisible sensor for folks dwelling with diabetes to handle their want for steady correct glucose and ketone monitoring with an improved person expertise. Indigo exploits groundbreaking photonics expertise answerable for revolutionizing the Web to rework diabetes administration. Indigo is predicated in Ghent, Belgium. Discover out extra at www.indigomed.com.
About Indigo Diabetes’s CMM sensor
Indigo Diabetes’s CMM sensor is a small spectrometer-on a-chip to observe in-vivo concurrently and constantly a number of metabolites. The inert, miniature built-in silicon photonics spectrometer chip measures the absorption of sunshine within the interstitial fluid to quantify the focus of a number of metabolites concurrently with out using enzymes or fluorophores. As soon as inserted below the pores and skin the CMM sensor is invisible to the bare eye and can join securely and wirelessly to cellular units to indicate and seize the focus profiles of the metabolites for the person. A chargeable sensor battery powers the measurements. It’s anticipated that the sensor could have a lifetime as much as 2 years. Preclinical research have efficiently demonstrated proof of idea with promising accuracy.
Indigo Diabetes N.V.
Dr Danaë Delbeke, CEO
E mail: [email protected]
Consilium Strategic Communications
Ashley Tapp, Alexandra Harrison, Isobel McLeod
Tel: +44 (0)20 3709 5700
E mail: [email protected]